

Subacute Sclerosing Panencephalitis

Background

Subacute sclerosing panencephalitis (SSPE) is a rare, late complication of measles and is invariably fatal. Its incidence in Australia is not known. Despite the availability of vaccination, a large nationwide epidemic of measles occurred between mid-1992 and mid-1995, with over 4,500 cases of measles being notified in 1993. Because there is a considerable delay between measles infection and onset of SSPE, some children affected in this epidemic may still not present for several years.

Measles vaccination first became available in Australia in 1968. A two-dose measles-mumps-rubella (MMR) vaccination strategy for children aged twelve months and in early adolescence was widely implemented by 1994. In 1998, all primary school children received a second dose of MMR vaccine. From 1998, both MMR doses will be given prior to primary school entry.

Objectives

- to estimate the incidence of SSPE in Australia
- to determine the proportion of children with SSPE who have a prior history of measles and to establish at what age measles occurred
- to determine the proportion of children with SSPE who have a prior history of measles immunisation and to establish at what age immunisation was given
- to determine whether there is an over-representation of any ethnic group or children born outside Australia in children with SSPE

Case definition

Any child less than 16 years of age with a typical history of SSPE; ie. insidious onset of mental deterioration followed by development of progressive motor dysfunction, dementia and decerebration and ultimately death

and either

- a) Raised measles antibody titres in the CSF or*
 - b) EEG changes showing “periodic complexes” typical of SSPE or*
 - c) Typical histopathological features of the brain at autopsy or*
- Any combination of a), b) or c).*

Results and discussion

In 1998 two notifications were received, one of which was a duplicate report. The child notified was a 14 year old Melanesian boy from Vanuatu who was not an Australian citizen. He had a history of possible measles

infection (diagnosed clinically) at uncertain age and his vaccination status was unknown.

Between 1995 and 1998 inclusive, there were eleven notifications of SSPE. All questionnaires were returned and indicated that four notifications were duplicates and one was an error. For one case the questionnaire provided minimal further information. Five children with SSPE had known onset of symptoms before 16 years of age (Table 12). None had a definite history of measles vaccination.

Table 12 Subacute sclerosing panencephalitis, 1995-1997

Cases	Year of Diagnosis	Vaccinated	Measles Infection	Onset of symptoms	Age at diagnosis	Place of Birth	Australian citizen
Case 1	1995	Possible	10m	14y	17y 6m	Australia	Yes
Case 2	1995	Don't know	Don't know	15y 6m	16y 6m	Australia	Yes
Case 3	1995	Possible	Possible	13y 2m	13y 4m	Australia	Yes
Case 4	1996	Possible	9m	15y 6m	15y 11m	Philippines	Yes
Case 5	1997	N/A*	N/A*	N/A	N/A	Malaysia	No
Case 6	1998	Don't know	Possible	14y 6m	14y 7m	Vanuatu	No

*Not Applicable

Two children had a definite history of measles infection; both in infancy. In these children the delay between measles infection and onset of symptoms of SSPE was 13 years and two months in one child and 14 years and nine months in the other.

The delay between onset of symptoms and diagnosis ranged from one month to three and a half years.

All children had consistent EEG changes and elevated CSF measles antibody titres. One child also had features of ‘subacute encephalitis’ on brain biopsy.

On the basis of these four cases in Australian children, this study suggests an incidence of 0.02/100,000 per annum in children diagnosed under 16 years of age for the period 1995-8.

Conclusion

Subacute sclerosing panencephalitis is extremely rare in the paediatric age group and is likely to become less common with the introduction of the two dose MMR by primary school entry. Due to the long delay between measles infection or immunisation and onset of symptoms of SSPE, it is likely that additional cases are being diagnosed beyond 16 years of age by adult physicians.

Investigators

Dr Jeffrey Hanna, Tropical Public Health Unit, PO Box 1103, Cairns QLD 4870 Tel: 07 4050 3600 Fax: 07 4031 1440

Dr Ross Messer, Flecker House, 5 Upward Street, Cairns QLD 4870

Clinical Associate Professor Peter Procopis, Executive Director, New Children’s Hospital, PO Box 3515, Parramatta NSW 2124